Identification of new targets for therapy of osteolytic bone disease in multiple myeloma
Ø Hjertner1, T Standal, M Børset
1Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. oyvind.hjertner@medisin.ntnu.no
Abstract:
One of the most characteristic features of multiple myeloma is the development of osteolytic bone lesions. Myeloma-associated bone disease is caused by an increase in osteoclastic bone resorption and a decrease in osteoblastic new bone formation. Insight into the molecular mechanisms of osteoclastogenesis has been provided by the detection of receptor activator of NF-kappaB ligand (RANKL), its specific receptor (RANK) and its decoy receptor antagonist osteoprotegerin (OPG). The RANK signaling system is abnormally regulated in multiple myeloma and targeting this system may ameliorate myeloma bone disease. Less is known about the development of osteoblastic dysfunction, and further knowledge about the interaction between myeloma cells and osteoblasts is required. The aim of this review is to focus on the principles of bone biology for a better understanding of the development of myeloma bone disease and to identify possible therapeutic targets.
Insights
Multiple myeloma causes bone lesions by increasing osteoclast activity and decreasing osteoblast function. Targeting the RANK signaling pathway may offer therapeutic benefits for myeloma bone disease.
Area of Science:
- Bone Biology
- Oncology
- Pathophysiology
Background:
- Multiple myeloma frequently causes osteolytic bone lesions, characterized by increased osteoclastic bone resorption and decreased osteoblastic bone formation.
- The receptor activator of NF-kappaB ligand (RANKL)/RANK/osteoprotegerin (OPG) system is crucial for osteoclastogenesis and is dysregulated in multiple myeloma.
- Understanding the interaction between myeloma cells and osteoblasts is essential for addressing osteoblastic dysfunction.
Purpose of the Study:
- To review the fundamental principles of bone biology relevant to multiple myeloma.
- To elucidate the mechanisms underlying myeloma-associated bone disease.
- To identify potential therapeutic targets for myeloma bone disease.
Main Methods:
- Review of existing literature on bone biology, multiple myeloma, and related molecular pathways.
- Analysis of the roles of RANKL, RANK, and OPG in myeloma bone disease.
- Exploration of osteoblast-myeloma cell interactions.
Main Results:
- The RANK signaling pathway is implicated in the pathogenesis of myeloma bone disease.
- Dysregulation of osteoclast and osteoblast activity contributes significantly to bone lesions.
- Further research into osteoblast dysfunction and cell-cell interactions is warranted.
Conclusions:
- Targeting the RANK signaling system presents a potential therapeutic strategy for myeloma bone disease.
- A comprehensive understanding of bone biology is key to developing effective treatments.
- Identifying novel therapeutic targets is crucial for managing bone complications in multiple myeloma.
